Related Experiment Videos
Expression and long-term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia
D R Vanhaeke1, M C Béné, R Garand
1Laboratoire d'Hématologie, Hôpital Cimiez, Nice, France.
Insights
CD34 expression in acute lymphoblastic leukemia (ALL) did not show significant long-term benefit. While CD34+ B-lineage ALL had fewer early relapses, overall survival curves for CD34+ and CD34- ALL patients merged over time.
Area of Science:
- Hematology
- Oncology
- Immunophenotyping
Background:
- Acute lymphoblastic leukemia (ALL) is a heterogeneous malignancy.
- CD34 expression is a marker used in ALL immunophenotyping.
- Understanding the prognostic significance of CD34 in ALL is crucial for treatment stratification.
Purpose of the Study:
- To analyze the clinical and laboratory characteristics of acute lymphoblastic leukemia (ALL) based on CD34 expression.
- To evaluate the long-term evolution and prognostic impact of CD34+ versus CD34- ALL in adults and children.
Main Methods:
- Retrospective analysis of 156 patients (66 adults, 90 children) with ALL.
- Classification of patients into CD34-positive (CD34+) and CD34-negative (CD34-) groups at diagnosis.
- Comparison of clinical features, laboratory data, and long-term outcomes (event-free survival, relapse rates).
Main Results:
- CD34+ ALL was more frequent in adult B-lineage ALL (p = .003).
- Higher white blood cell counts were observed in CD34- B-lineage ALL (children) and CD34- T-lineage ALL (adults).
- Children with CD34+ ALL had longer event-free follow-up (p = .04); however, survival curves for CD34+ and CD34- ALL patients merged after 2 years.
Conclusions:
- CD34 expression in ALL does not appear to confer a significant long-term survival benefit.
- CD34+ B-lineage ALL showed a trend towards fewer early relapses post-remission induction.
- Further research may be needed to fully elucidate the role of CD34 in ALL prognosis and treatment.
Abstract:
Clinical and laboratory characteristics at diagnosis, and long-term (up to 7 years) evolution, were analysed in 156 patients (66 adults and 90 children) with acute lymphoblastic leukemia (ALL), according to the expression of CD34. Eighty-three patients had CD34+ and 73 patients CD34- blasts at diagnosis. In adults, CD34+ ALL was more often of B-lineage (p = .003). White blood cell counts were higher both in children with CD34-B-lineage ALL (p = .02) and adults with CD34-T-lineage ALL (p - .05). Adult patients with CD34-T-lineage ALL were older (p = .04) and had more frequent splenic or liver enlargement (p = .02). Children with CD34+ ALL had a significantly (p = .04) longer event-free follow-up than CD34- children. Survival curves showed that after induction of remission, relapses were less frequent during the first 2 years for patients with CD34+ B-lineage ALL. After 2 years, however, event-free survival curves of CD34+ and CD34- patients merged. Thus it seems that CD34+ has no significant benefit for ALL patients.